MOTS-c (Mitochondrial Peptide)

MOTS-c in the Published Literature

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

MOTS-c appears in roughly 250 indexed PubMed records since 2015. Three papers anchor the field: the 2015 discovery in Cell Metabolism, the 2018 nuclear translocation finding, and the 2021 exercise study in Nature Communications. The literature is overwhelmingly preclinical, with human work largely observational.

Key facts

Indexed PubMed records
~250
First publication
3 March 2015
Discovery paper
PMID 25738459, Cell Metabolism
Nuclear signalling
PMID 29983246, Cell Metabolism 2018
Exercise study
PMID 33473109, Nature Communications 2021
Evidence base
Predominantly cell and rodent models
Human data
Largely observational
Registered clinical trials
None established for administration

The three anchor papers

The 2015 Cell Metabolism paper by Lee, Zeng, Drew and colleagues identified the peptide and reported its metabolic effects in mouse models. The 2018 Cell Metabolism paper by Kim, Son and Benayoun reported nuclear translocation under metabolic stress. The 2021 Nature Communications paper by Reynolds, Lai, Woodhead and colleagues reported exercise induction, with roughly 12-fold skeletal-muscle and 1.6-fold circulating increases in humans. Nearly everything else in the field builds on one of these three.

What kind of evidence this is

The great majority of the literature is preclinical: cultured cells and rodent models. Human involvement has largely taken the form of measuring endogenous concentrations and correlating them with age, fitness or metabolic state. That is a different category of evidence from an interventional trial, and the distinction governs what any of it can support.

Research material referenced

MOTS-C 10mg, third-party HPLC tested

Buy MOTS-C · £24.99

Why correlation is the ceiling for the human data

Observing that circulating MOTS-c is lower in older or less metabolically healthy people establishes an association. It does not establish direction (the concentration could be a consequence of mitochondrial state rather than a cause of anything), and it certainly does not establish what administration would do. This is the inference the secondary literature most commonly overreaches on.

Where the newer work is going

More recent publications have examined mitochondrial respiration in disease models, including work on the diabetic heart, and on muscle mitochondrial bioenergetics in a PGC-1α/AMPK-dependent manner. These extend the mechanistic picture within the same preclinical frame rather than moving the evidence into a new category.

How to search it yourself

PubMed indexes the field under 'MOTS-c'. Filtering by publication type separates reviews from primary research, and checking the model organism in the abstract is the fastest way to establish what kind of evidence a given paper actually offers. Reviews are useful for orientation but inherit the limitations of what they summarise.

Frequently asked questions

Are there clinical trials of MOTS-c administration?

No established registered interventional trials of administration. The human literature measures endogenous concentrations rather than testing the peptide as an intervention.

Which paper should I read first?

The 2015 Cell Metabolism discovery paper, PMID 25738459. It establishes the peptide, its origin and its mechanism, and everything since references it.

Is 250 papers a large literature?

Modest. For comparison, well-established compounds accumulate thousands. It reflects a field roughly a decade old and still mostly preclinical.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MOTS-c (Mitochondrial Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.